Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Instylan is a sterile 0.16% sodium hyaluronate (hyaluronic acid) solution classified as a Class IIa medical device and used for intravesical bladder irrigation to restore the glycosaminoglycan (GAG) barrier of the urothelium in conditions such as interstitial cystitis/bladder pain syndrome, recurrent or chronic cystitis, and radiation- or chemotherapy-induced hemorrhagic cystitis.[1][3][5][7][11][13][14] By forming a viscous, elastic film over the bladder mucosa and penetrating into the submucosa, exogenous hyaluronic acid replenishes the defective GAG layer, reduces permeability to toxic urinary components and bacterial adhesion, and thereby attenuates inflammation, pain, urgency, frequency, and hematuria.[1][7][11][13][14] The product is supplied in 50 ml single-use containers for instillation via urological catheter, typically administered weekly for several weeks followed by monthly maintenance, and is marketed in multiple countries through partners such as Red Leaf Medical and others.[3][5][7][8][9][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Instylan.